Login / Signup

Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism.

Edward V NunesAdam BisagaEvgeny M KrupitskyNarinder NangiaBernard L SilvermanSarah C AkermanMaria A Sullivan
Published in: Addiction (Abingdon, England) (2019)
Extended-release injection naltrexone was effective at reducing the risk of dropout from opioid use disorder treatment after an episode of opioid use. Just under a third of patients (31%) on XR-NTX had no opioid-positive urine tests across the trial, but the hypothesis that this would differ from placebo (20%) was not confirmed.
Keyphrases
  • end stage renal disease
  • study protocol
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • phase iii
  • clinical trial
  • chronic pain
  • randomized controlled trial
  • prognostic factors
  • peritoneal dialysis
  • phase ii